🟢 Kailera Therapeutics is trading 6.94% up in pre-market after progress toward global Phase 3 obesity trials

Kailera Therapeutics is trading 6.94% up now in pre-market at $19.88 after its August 12, 2026, second-quarter report highlighted progress toward global Phase 3 obesity trials and an oral ribupatide IND.

• Ribupatide oral Phase 3 trials are planned for the first half of 2027.
• The company reported $1.17 billion in cash and marketable securities, supporting operations into mid-2028.
• Net loss widened to $111.3 million, and EPS came in below estimates, creating mixed results.